277 related articles for article (PubMed ID: 16831964)
1. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Weinstock-Guttman B; Ramanathan M; Lincoff N; Napoli SQ; Sharma J; Feichter J; Bakshi R
Arch Neurol; 2006 Jul; 63(7):957-63. PubMed ID: 16831964
[TBL] [Abstract][Full Text] [Related]
2. Brain abnormalities in neuromyelitis optica.
Pittock SJ; Lennon VA; Krecke K; Wingerchuk DM; Lucchinetti CF; Weinshenker BG
Arch Neurol; 2006 Mar; 63(3):390-6. PubMed ID: 16533966
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica treatment: analysis of 36 patients.
Bichuetti DB; Lobato de Oliveira EM; Oliveira DM; Amorin de Souza N; Gabbai AA
Arch Neurol; 2010 Sep; 67(9):1131-6. PubMed ID: 20837859
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.
Kim SH; Kim W; Park MS; Sohn EH; Li XF; Kim HJ
Arch Neurol; 2011 Apr; 68(4):473-9. PubMed ID: 21149806
[TBL] [Abstract][Full Text] [Related]
5. [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
Komori M; Tanaka M; Muramoto E; Ohno M; Matsumoto R; Murase N; Kitagawa N; Saida T
Rinsho Shinkeigaku; 2007 Jul; 47(7):401-6. PubMed ID: 17710882
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
Singhal BS; Geeta S; Hundalani SG; Menon S
Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
[TBL] [Abstract][Full Text] [Related]
8. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
[TBL] [Abstract][Full Text] [Related]
9. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
[TBL] [Abstract][Full Text] [Related]
10. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of pediatric neuromyelitis optica.
Lotze TE; Northrop JL; Hutton GJ; Ross B; Schiffman JS; Hunter JV
Pediatrics; 2008 Nov; 122(5):e1039-47. PubMed ID: 18838462
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.
Ghezzi A; Bergamaschi R; Martinelli V; Trojano M; Tola MR; Merelli E; Mancardi L; Gallo P; Filippi M; Zaffaroni M; Comi G;
J Neurol; 2004 Jan; 251(1):47-52. PubMed ID: 14999489
[TBL] [Abstract][Full Text] [Related]
13. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
[TBL] [Abstract][Full Text] [Related]
14. Interferon-beta(1b) treatment in neuromyelitis optica.
Tanaka M; Tanaka K; Komori M
Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215
[TBL] [Abstract][Full Text] [Related]
15. Expanding the spectrum of neuromyelitis optica: friend or foe?
Behbehani R
Curr Opin Ophthalmol; 2007 Nov; 18(6):459-62. PubMed ID: 18162996
[TBL] [Abstract][Full Text] [Related]
16. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica.
Weinstock-Guttman B; Miller C; Yeh E; Stosic M; Umhauer M; Batra N; Munschauer F; Zivadinov R; Ramanathan M
Mult Scler; 2008 Sep; 14(8):1061-7. PubMed ID: 18573816
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study.
Cabre P; Olindo S; Marignier R; Jeannin S; Merle H; Smadja D;
J Neurol Neurosurg Psychiatry; 2013 May; 84(5):511-6. PubMed ID: 23138769
[TBL] [Abstract][Full Text] [Related]
18. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.
Llufriu S; Castillo J; Blanco Y; Ramió-Torrentà L; Río J; Vallès M; Lozano M; Castellà MD; Calabia J; Horga A; Graus F; Montalban X; Saiz A
Neurology; 2009 Sep; 73(12):949-53. PubMed ID: 19770470
[TBL] [Abstract][Full Text] [Related]
19. Neuromyelitis optica in France: a multicenter study of 125 patients.
Collongues N; Marignier R; Zéphir H; Papeix C; Blanc F; Ritleng C; Tchikviladzé M; Outteryck O; Vukusic S; Fleury M; Fontaine B; Brassat D; Clanet M; Milh M; Pelletier J; Audoin B; Ruet A; Lebrun-Frenay C; Thouvenot E; Camu W; Debouverie M; Créange A; Moreau T; Labauge P; Castelnovo G; Edan G; Le Page E; Defer G; Barroso B; Heinzlef O; Gout O; Rodriguez D; Wiertlewski S; Laplaud D; Borgel F; Tourniaire P; Grimaud J; Brochet B; Vermersch P; Confavreux C; de Seze J
Neurology; 2010 Mar; 74(9):736-42. PubMed ID: 20194912
[TBL] [Abstract][Full Text] [Related]
20. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
